Evolent Announces Second Quarter 2024 Results Revenue of $647.1 million, an increase of $178.0 million or 37.9% , from the three months ended

Evolent Announces Second Quarter 2024 Results

Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.

Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.

Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.

Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.

Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.

WASHINGTON (August 8, 2024) - Evolent Health, Inc. (NYSE EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended June 30, 2024.

Seth Blackley, co-founder and Chief Executive Officer of Evolent stated, "Evolent revenue increased by over 35% year-over-year and we delivered consistent profitability and cash flow. We have also made significant progress toward revenue fee increases consistent with the higher disease rates in the market - underscoring our ability to perform and bring clinical value to our customers in both higher and lower utilization environments.

Mr. Blackley continued, "We believe the combination of our strong sales performance, the significant progress on updated rates and the clinical value we bring to our customers gives us confidence in delivering on our 2024 revised Adjusted EBITDA guidance range and on our 2024 $300 million exit run rate profitability target."

Highlights from the quarter ended June 30, 2024 include (in thousands, except for average PMPM fees and revenue per case)

Evolent highlighted the following four new revenue agreements, two in Performance Suite and two within Specialty Technology and Services, as defined below

Expanded to two new states in the Performance Suite for oncology with an existing enterprise client

Executed a significant revenue cross-sale of oncology and other Specialty Technology and Services solutions to a large western Blues plan and

Expansion with a Midwest Blue Cross Blue Shield plan to expand the Company's musculoskeletal Specialty Technology and Services solutions to Medicare Advantage members.

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss non-GAAP financial measures. Definitions of the non-GAAP financial measures presented herein as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings release. See Financial Statement Presentation and Non-GAAP Financial Measures for more information.

Evolent Health, Inc. reported the following results in accordance with U.S. generally accepted accounting principles ("GAAP") (in thousands, except for per share data)

Total cash and cash equivalents was $101.3 million as of June 30, 2024.

Evolent Health, Inc. reported the following adjusted results (in thousands, except for per share data)

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to acquisitions and other events. Such items may, from time to time, include loss on repayment extinguishment of debt gain (loss) from equity method investees, change in fair value of contingent consideration, change in tax receivable agreement liability, other income (expense), gain (loss) on disposal of non-strategic assets, right-of-use asset impairments, repositioning costs, stock-based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock, acquisition-related costs and certain other items the company believes to be non-indicative of its ongoing operations. Such adjustments may be affected by changes in ongoing assumptions, judgements, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments are not currently determinable but may be significant.

Third Quarter 2024 Guidance

For the three months ended September 30, 2024, revenue is expected to be in the range of $615.0 million to $635.0 million. Adjusted EBITDA is expected to be in the range of $60.0 million to $68.0 million. The revenue outlook for the three months ended September 30, 2024 is impacted by an expected one-time true-down related to the narrower risk scope in certain markets that is neutral to the Company's Adjusted EBITDA outlook.

The Company noted that its outlook for the third quarter and its full year 2024 guidance are based on the following assumptions first, disease prevalence and acuity to remain stable at the average levels of the first half of 2024 second, the capture of anticipated rate increases expected to go live in the third quarter third, continuing to successfully execute as expected on the underlying maturation of the Performance Suite revenue portfolio and fourth, the go-live of announced new business.

Full Year 2024 Guidance

For the year ending December 31, 2024, revenue is expected to be in the range of approximately $2.56 billion to $2.60 billion and Adjusted EBITDA is expected to be in the range of approximately $230.0 million to $245.0 million. In addition to the assumptions underlying the third quarter guidance, our updated ranges for the year are based on our expectations of the timing of anticipated rate increases from clients for Performance Suite beginning in 2024 as well as new go-lives. Beginning in August, we are reallocating certain engineering expenses towards the Machinify roll out. This will have a temporary effect of lowering our software capitalization rate and increasing our operating expenses by $5 million, primarily in the fourth quarter of 2024. We therefore expect this temporary shift of dollars from capitalized expenses to operating expenses to reduce Adjusted EBITDA but having no impact on cash flow. The Company expects these costs to return to capitalized expenses by the end of December 2024 and it continues to forecast greater than $150 million in operating cash flow for 2024.

In revising our Adjusted EBITDA outlook for the year, the Company prioritized setting the appropriate rates for the balance of 2024 and for 2025 over retrospective rate increases based on the partnership dynamics with our payers in an environment where they are under pressure. This Business Outlook section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in Forward Looking Statements - Cautionary Language and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ( SEC ).

Additional Outlook Information

For the year ending December 31, 2024, the Company expects

Cash deployed for capitalized software development of approximately $25 million.

Cash flow from operations of at least $150 million.

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this evening, August 8, 2024, at 5 00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http ir.evolent.com. To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the Evolent Health call. Participants are

advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

Evolent (NYSE EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

New Revenue Agreements

Beginning with the first quarter of 2024, Evolent began reporting the number of new revenue agreements signed for Performance Suite, Specialty Technology and Services Suite, Administrative Services and Case-based products. A new revenue agreement includes incremental revenue to the Company reflecting contracts for services to both new partner entities, corporations or health plans as well as additional sales to existing partners. New revenue agreements may include incremental services, geographic, or line of business expansions or a combination thereof. The conversion of Specialty Technology and Services Suite contracts to Performance Suite are also included in this definition. The company does not count renewals for existing scope, growth of membership within an existing contract scope or transaction related purchase agreements, if applicable, in this metric.

Lives on Platform and Per Member Per Month ("PMPM") Fee

Performance Suite Lives on Platform are calculated by summing monthly members covered for specialty care services for contracts not under ASO arrangements, plus members managed by Complex Care in risk arrangements and divided by the number of months in the period. Specialty Technology and Services Suite Lives on Platform are calculated by summing monthly members covered for oncology, cardiology, musculoskeletal, advanced imaging and other diagnostic specialty care services for contracts under ASO arrangements divided by the number of months in the period. Administrative Services Lives on Platform are calculated by summing monthly members covered for administrative services implementation and core performance services divided by the number of months in the period. Cases are calculated by summing the number of individuals receiving services through our surgery management and advanced care planning programs in a given period. Members covered for more than one category are counted in each category.

Performance Suite Average PMPM fee is defined as revenue pertaining to our Performance Suite during the period reported divided by Performance Suite Lives on Platform for the period divided by the number of months in the period. Specialty Technology and Services Suite Average PMPM fee is defined as revenue pertaining to the Specialty Technology and Services Suite during the period reported divided by Specialty Technology and Services Suite Lives on Platform for the period divided by the number of months in the period. Administrative Services Average PMPM fee is defined as revenue pertaining to the Administrative Services during the period reported divided by the Administrative Services Lives on Platform for the period divided by the number of months in the period. Revenue per Case is calculated by the revenue pertaining to surgery management and advanced care planning programs divided by the number of cases for a given period.

Average Unique Members are calculated by summing members covered by our Performance Suite, Specialty Technology and Services Suite and Administrative Services. In cases where partners cross between multiple solutions, we only capture members from the solution with the maximum number of members.

Management uses Lives on Platform, PMPM fees, Cases, Revenue per Case and Average Unique Members because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.

Evolent Health, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(unaudited, in thousands, except per share data)

Evolent Health, Inc.

Consolidated Balance Sheets

Evolent Health, Inc.

Consolidated Statements of Cash Flows

(in thousands, unaudited)

Non-GAAP Financial Measures

The Company views the following activities as integral to understanding its non-GAAP financial measures

Repositioning costs include severance, termination benefits and related payroll taxes of $31.0 thousand and $1.8 million, dedicated employee costs of $0.0 million and $1.2 million, third-party professional services of $0.6 million and $4.1 million and office space consolidation costs of $0.0 million and $3.5 million for the three and six months ended June 30, 2024, respectively. Repositioning costs are not part of Evolent's normal course of business and are incurred when there is a business reason to enact a repositioning plan. Adjusting for these costs gives a better view of the Evolent's normal operating costs. We only adjust costs that (i) are included within selling, general and administrative expenses on the consolidated statement of operations and comprehensive income (loss), (ii) meet the criteria outlined within the respective repositioning plan and (iii) do not relate to normal business operations or ongoing activities.

Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent's integrated technology platform and costs related to the consolidation of internal operations, strategies, processes and platforms. Dedicated employee costs are limited to employees that will have no role in ongoing operations and have no planned role at Evolent once the repositioning activities are completed.

Professional services costs primarily relate to services provided by a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.

Office space consolidation costs include early termination penalties and associated expenses.

Acquisition-related costs include but are not limited to integration consultants, financial advisory and banking services, external valuation and accounting advisory services, legal fees and transaction bonuses paid to certain employees.

Purchase accounting adjustments include amortization expense on intangible assets such as corporate trade names, customer, relationships, provider network contracts and existing technology related to acquisitions and business combinations. We believe it is important for the reader to understand that revenue generated from acquisitions is included within revenue in calculating adjusted income to common shareholders however amortization expense from acquired intangible assets is excluded in determining adjusted income to common shareholders because it does not directly relate to the services performed for the Company's customers.

In addition to disclosing financial results that are determined in accordance with GAAP, we present Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Income Attributable to Common Shareholders, Adjusted Income per Common Share Attributable to Common Shareholders, Adjusted EBITDA and Adjusted EBITDA Margin, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.

Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, acquisition-related costs and repositioning costs. Management believes Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are useful to investors, because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not a representative component of the day-to-day operating performance of our business, and are useful to management as supplemental performance measures.

Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, benefit from (provision for) income taxes, depreciation and amortization expenses, change in the tax receivable agreement liability, gain (loss) from equity method investees, change in fair value of contingent consideration, other income (expense), net, right-of-use asset impairment, repositioning costs, stock-

based compensation expense, severance costs, dividends and accretion on Series A Preferred Stock and acquisition-related costs.

Management believes that Adjusted EBITDA is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA as a supplemental performance measure because the removal of repositioning costs, acquisition-related costs, severance or non-cash items (e.g. depreciation, amortization, and stock-based compensation expense) allows us to focus on operational performance.

Adjusted EBITDA Margin is as defined Adjusted EBITDA divided by Revenue. Management believes that this measure is useful to investors because it allows further insight into the period over period operational performance. Management also uses Adjusted EBITDA Margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time.

Adjusted Income Attributable to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain (loss) from equity method investees, other income (expense), net, benefit from (provision for) income taxes, change in fair value of contingent consideration, change in tax receivable agreement liability, purchase accounting adjustments, right-of-use asset impairment, repositioning costs, stock-based compensation expenses, severance costs, dividends and accretion on Series A Preferred Stock and acquisition-related costs.

Adjusted Income per Share Attributable to Common Shareholders is defined as Adjusted Income Attributable to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.

Management believes that Adjusted Income Attributable to Common Shareholders and Adjusted Income per Share Attributable to Common Shareholders are useful to investors because excluding non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows investors to focus on operational performance. These measures are also useful to management for the same reason.

These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.

Evolent Health, Inc.

Reconciliation of Adjusted Results of Operations

(in thousands, unaudited)

Evolent Health, Inc.

Reconciliation of Adjusted EBITDA to Net Income (Loss)

Attributable to Common Shareholders of Evolent Health, Inc.

Evolent Health, Inc.

Reconciliation of Adjusted Income Attributable to Common Shareholders to

Net Loss Attributable to Common Shareholders

(in thousands, except per share data)

FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE

Certain statements made in this report and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "estimate," "aim," "predict," "potential," "continue," "plan," "project," "will," "should," "shall," "may," "might" and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions expansions, the adoption and launch of a unified brand, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.

These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements. Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others

risks relating to our ability to efficiently integrate NIA into our operations

the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate

our ability to terminate certain leases and recognize impairment charges in connection with our repositioning plan

evolution of the healthcare regulatory and political framework

uncertainty in the health care regulatory framework, including the potential impact of policy changes

our ability to offer new and innovative products and services and our ability to keep pace with industry standards, technology and our partners' needs

risks related to completed and future acquisitions, investments, alliances and joint ventures, which could divert management resources, result in unanticipated costs or dilute our stockholders

the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes

risks relating to our ability to maintain profitability for our total cost of care and performance-based contracts and products, including capitation and risk-bearing contracts

our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures